 Dolutegravir DTG is an integrase strand transfer inhibitor I that supports once-daily dosing without the need for pharmacokinetic boosting and may be co-formulated with other antiretrovirals into a single-tablet regimen STR. With people living with HIV with injection drug use IDU being more prone to unplanned antiretroviral therapy ART discontinuation and suboptimal adherence, DTG offers a high genetic barrier to resistance, a profile that reduces drug-drug interactions, with better tolerability and its availability as single tablet regimen STR combined with abacavir and lamivudine ABC3TC is likely to improve adherence. 